226 related articles for article (PubMed ID: 29462967)
1. Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
Neuber C; Belter B; Meister S; Hofheinz F; Bergmann R; Pietzsch HJ; Pietzsch J
Molecules; 2018 Feb; 23(2):. PubMed ID: 29462967
[TBL] [Abstract][Full Text] [Related]
2. The Pyrazolo[3,4-
Neuber C; Tröster A; Löser R; Belter B; Schwalbe H; Pietzsch J
Molecules; 2020 Nov; 25(21):. PubMed ID: 33153234
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4.
Mamat C; Mosch B; Neuber C; Köckerling M; Bergmann R; Pietzsch J
ChemMedChem; 2012 Nov; 7(11):1991-2003. PubMed ID: 23042640
[TBL] [Abstract][Full Text] [Related]
4. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.
Héroult M; Schaffner F; Pfaff D; Prahst C; Kirmse R; Kutschera S; Riedel M; Ludwig T; Vajkoczy P; Graeser R; Augustin HG
Mol Cancer Res; 2010 Oct; 8(10):1297-309. PubMed ID: 21047731
[TBL] [Abstract][Full Text] [Related]
5. The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand.
Yang NY; Lopez-Bergami P; Goydos JS; Yip D; Walker AM; Pasquale EB; Ethell IM
Pigment Cell Melanoma Res; 2010 Oct; 23(5):684-7. PubMed ID: 20649938
[No Abstract] [Full Text] [Related]
6. Inhibition of tumor growth and angiogenesis by soluble EphB4.
Martiny-Baron G; Korff T; Schaffner F; Esser N; Eggstein S; Marmé D; Augustin HG
Neoplasia; 2004; 6(3):248-57. PubMed ID: 15153337
[TBL] [Abstract][Full Text] [Related]
7. Experimental hypoxia does not influence gene expression and protein synthesis of Eph receptors and ephrin ligands in human melanoma cells in vitro.
Reissenweber B; Mosch B; Pietzsch J
Melanoma Res; 2013 Apr; 23(2):85-95. PubMed ID: 23358429
[TBL] [Abstract][Full Text] [Related]
8. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization.
Yang NY; Pasquale EB; Owen LB; Ethell IM
J Biol Chem; 2006 Oct; 281(43):32574-86. PubMed ID: 16950769
[TBL] [Abstract][Full Text] [Related]
9. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
10. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
[TBL] [Abstract][Full Text] [Related]
11. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
Huang X; Yamada Y; Kidoya H; Naito H; Nagahama Y; Kong L; Katoh SY; Li WL; Ueno M; Takakura N
Cancer Res; 2007 Oct; 67(20):9800-8. PubMed ID: 17942910
[TBL] [Abstract][Full Text] [Related]
12. Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models.
Huang M; Xiong C; Lu W; Zhang R; Zhou M; Huang Q; Weinberg J; Li C
Mol Imaging Biol; 2014 Feb; 16(1):74-84. PubMed ID: 23918654
[TBL] [Abstract][Full Text] [Related]
13. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
[TBL] [Abstract][Full Text] [Related]
14. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
Xiong C; Wen Y; Zhao J; Yin D; Xu L; Chelariu-Raicu A; Yao C; Leng X; Liu J; Chaudhari RR; Zhang S; Sood AK; Li C
Sci Rep; 2020 Jan; 10(1):520. PubMed ID: 31949258
[TBL] [Abstract][Full Text] [Related]
15. Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Broggini T; Piffko A; Hoffmann CJ; Ghori A; Harms C; Adams RH; Vajkoczy P; Czabanka M
Oncogene; 2020 Nov; 39(47):7063-7075. PubMed ID: 32989254
[TBL] [Abstract][Full Text] [Related]
16. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
[TBL] [Abstract][Full Text] [Related]
17. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Chen Y; Zhang H; Zhang Y
Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
[TBL] [Abstract][Full Text] [Related]
18. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
Randolph ME; Cleary MM; Bajwa Z; Svalina MN; Young MC; Mansoor A; Kaur P; Bult CJ; Goros MW; Michalek JE; Xiang S; Keck J; Krasnoperov V; Gill P; Keller C
PLoS One; 2017; 12(8):e0183161. PubMed ID: 28817624
[TBL] [Abstract][Full Text] [Related]
19. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
[TBL] [Abstract][Full Text] [Related]
20. EphrinB2 and EphB4 expression in pterygia: new insights and preliminary results.
Xue C; Huang Z; Wang J; Dong Y; Zhou X
Can J Ophthalmol; 2009 Apr; 44(2):185-8. PubMed ID: 19491953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
